Aug 2, 2016 1 min read

CANONSBURG – Mylan N.V. said Tuesday that Meda shareholders representing 94 percent of the Swedish specialty drugmaker’s shares have accepted Mylan’s offer to purchase the company for $7.2 billion.

Mylan, which is incorproated in the Netherlands, but runs the company from its Southpointe-based headquarters, Mylan will acquire a bigger geographic reach and a portfolio of specialty and over-the-counter drugs.

Upon closing, Meda will become a controlled subsidiary of Mylan.